LEADER 02587nam 2200565 a 450 001 9910138864903321 005 20200520144314.0 010 $a1-118-35680-2 010 $a1-283-89332-0 010 $a1-118-35678-0 035 $a(CKB)2550000000710765 035 $a(EBL)1098891 035 $a(OCoLC)794306445 035 $a(SSID)ssj0000784062 035 $a(PQKBManifestationID)11428760 035 $a(PQKBTitleCode)TC0000784062 035 $a(PQKB)11243278 035 $a(MiAaPQ)EBC1098891 035 $a(Au-PeEL)EBL1098891 035 $a(CaPaEBR)ebr10639275 035 $a(CaONFJC)MIL420582 035 $a(PPN)178889687 035 $a(EXLCZ)992550000000710765 100 $a20120522d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aProduction of plasma proteins for therapeutic use$b[electronic resource] /$fedited by Joseph Bertolini, Neil Goss, John Curling 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2013 215 $a1 online resource (510 p.) 300 $aDescription based upon print version of record. 311 $a0-470-92431-4 320 $aIncludes bibliographical references and index. 327 $asection 1. Introduction to plasma fractionation -- section 2. Plasma proteins for therapeutic use -- section 3. Pathogen safety of plasma products -- section 4. The pharmaceutical environment applied to plasma fractionation -- section 5. The market for plasma products and the economics of fractionation. 330 $aSets forth the state of the science and technology in plasma protein production With contributions from an international team of eighty leading experts and pioneers in the field, Production of Plasma Proteins for Therapeutic Use presents a comprehensive overview of the current state of knowledge about the function, use, and production of blood plasma proteins. In addition to details of the operational requirements for the production of plasma derivatives, the book describes the biology, development, research, manufacture, and clinical indications of essentially al 606 $aBlood proteins$xTherapeutic use 615 0$aBlood proteins$xTherapeutic use. 676 $a615.3/9 701 $aBertolini$b Joseph$0861541 701 $aGoss$b Neil$0861542 701 $aCurling$b J. M$g(John M.)$0861543 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910138864903321 996 $aProduction of plasma proteins for therapeutic use$91922635 997 $aUNINA LEADER 02697 am 22005893u 450 001 9910139090703321 005 20230621141129.0 010 $a1-351-66057-8 010 $a1-315-15978-3 010 $a1-351-66058-6 010 $a91-977071-1-2 035 $a(CKB)2560000000080638 035 $a(SSID)ssj0000409547 035 $a(PQKBManifestationID)12146484 035 $a(PQKBTitleCode)TC0000409547 035 $a(PQKBWorkID)10347826 035 $a(PQKB)10143075 035 $a(MiAaPQ)EBC4803571 035 $a(OCoLC)1011119580$z(OCoLC)980761233 035 $a(OCoLC-P)1011119580 035 $a(FlBoTFG)9781315159782 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45511 035 $a(EXLCZ)992560000000080638 100 $a20171110d2017 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDrug-Acceptor Interactions $eModeling Theoretical Tools to Test and Evaluate Experimental Equilibrium Effects 205 $aFirst edition. 210 $cCo-Action Publishing 210 1$aBoca Raton, FL :$cCRC Press,$d2017. 215 $a1 online resource (798 pages) $cillustrations 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a91-977071-0-4 320 $aIncludes bibliographical references at the end of each chapters. 330 2 $a"Drug-Acceptor Interactions: Modeling theoretical tools to test and evaluate experimental equilibrium effects suggests novel theoretical tools to test and evaluate drug interactions seen with combinatorial drug therapy. The book provides an in-depth, yet controversial, exploration of existing tools for analysis of dose-response studies at equilibrium or steady state. The book is recommended reading for post-graduate students and researchers engaged in the study of systems biology, networks, and the pharmacodynamics of natural or industrial drugs, as well as for medical clinicians interested in drug application and combinatorial drug therapy. Even people without mathematical skills will be able to follow the pros and cons of reaction schemes and their related distribution equations. Chapter 9 is a hands-on guide for software to plot, fit and analyze one's own data."--Provided by publisher. 606 $aDrug interactions 606 $aChemotherapy 610 $aDrugs 610 $atherapy 615 0$aDrug interactions. 615 0$aChemotherapy. 676 $a615.7045 700 $aBindslev$b Niels$0801082 801 0$bOCoLC-P 801 1$bOCoLC-P 906 $aBOOK 912 $a9910139090703321 996 $aDrug-Acceptor Interactions$91926723 997 $aUNINA LEADER 01093nas 2200409 c 450 001 9910893619103321 005 20250513224336.0 024 7 $aurn:nbn:de:bsz:16-diglit-206017 035 $a(CKB)5280000000199264 035 $a(DE-599)ZDB2750762-2 035 $a(DE-101)1046399063 035 $a(EXLCZ)995280000000199264 100 $a20140115b18211824 |y | 101 0 $ager 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCharis$erhein. Morgenzeitung für gebildete Leser$fhrsg. von Friedrich Karl Freiherrn von Erlach 210 31$aMannheim$aHeidelberg$cGroos$d1821-1824 210 1$aMannheim$cSchwan$d1821 215 $aOnline-Ressource 517 $aCharis 517 1 $aCharis 608 $aZeitung$2gnd-content 676 $a070 676 $a914.3 676 $a943 676 $a800 686 $a9,10$2ssgn 801 0$b0016 801 1$bDE-101 801 2$b9999 906 $aJOURNAL 912 $a9910893619103321 996 $aCharis$91244770 997 $aUNINA